RAD51 and endometrial cancer: A meta-analysis conducted by Zeng et al. [11] suggests that RAD51  rs1801320 (135G/C) polymorphism is a risk factor for three common gynecological tumors, i.e., breast, endometrial, and ovarian cancers, and especially for endometrial cancer.